<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16a, 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
For the Month of May, 2000
ALTAREX CORP.
(Exact name of Registrant as specified in its charter)
CAMPUS TOWER
#300, 8625 - 112 STREET
EDMONTON, ALBERTA, CANADA T6G 1K8
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports
under cover Form 20-F or Form 40-F.
Form 20-F X Form 40-F
----- -----
Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes No X
----- ---
<PAGE> 2
On May 12, 2000, AltaRex Corp. (the "Company") issued a press release
announcing that the Company planned to present data at the Immunology 2000
meeting, held on May 13, 2000, which would elucidate the mechanism by which the
Company believes OvaRex (TM) MAb induces tumor killing through interaction with
human-anti-mouse-antibodies. A copy of this press release is attached hereto as
Exhibit 99.1.
Exhibits
--------
99.1 Press release dated May 12, 2000
-2-
<PAGE> 3
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Company has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
ALTAREX CORP.
By: /s/ Edward M. Fitzgerald
---------------------------------------
Name: Edward M. Fitzgerald
Title: Senior Vice President and Chief
Financial Officer
Date: May 31, 2000
-3-
<PAGE> 4
INDEX TO EXHIBITS
EXHIBIT NO. DESCRIPTION
----------- -----------
99.1 Press Release dated May 12, 2000
-4-
